Surface Oncology (DB:QSOA) - Aandelenkoers, Nieuws & Analyse

QSOA Overzicht aandelen

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Meer informatie

QSOA fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft minder dan 1 jaar cash runway

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 2 meer risico's

Surface Oncology, Inc. Concurrenten

4SC

DB:VSC

€51.9m

Medigene

XTRA:MDG1

€20.6m

Heidelberg Pharma

XTRA:HPHA

€106.7m

2invest

XTRA:2INV

€63.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Surface Oncology
Historische aandelenkoersen
Huidige aandelenkoers	US$0.99
52 Week Hoogtepunt	US$1.41
52 Week Laag	US$0.52
Bèta	1.75
11 maand verandering	16.19%
3 maanden verandering	36.16%
1 Jaar Verandering	-27.10%
33 jaar verandering	-82.41%
5 jaar verandering	-88.77%
Verandering sinds IPO	-90.74%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	QSOA	DE Biotechs	DE Markt
7D	-0.7%	0.8%	0.8%
1Y	-27.1%	-18.3%	8.6%

Rendement versus industrie: QSOA presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -18.3 % opleverde.

Rendement versus markt: QSOA presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.6 % opleverde.

Prijsvolatiliteit

Is QSOA's price volatile compared to industry and market?
QSOA volatility
QSOA Average Weekly Movement	12.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van QSOA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van QSOA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	35	Rob Ross	www.surfaceoncology.com

Surface Oncology, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Surface Oncology zich tot de beurswaarde?
QSOA fundamentele statistieken
Marktkapitalisatie	€60.83m
Inkomsten(TTM)	-€86.46m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is QSOA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
QSOA resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$67.00m
Brutowinst	-US$67.00m
Overige uitgaven	US$25.50m
Inkomsten	-US$92.50m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.52
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde QSOA op de lange termijn?

Bekijk historische prestaties en vergelijking

QSOA Overzicht aandelen

Risicoanalyse

Surface Oncology, Inc. Concurrenten

DB:VSC

€51.9m

XTRA:MDG1

€20.6m

XTRA:HPHA

€106.7m

XTRA:2INV

€63.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021)

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021)

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

Revenue beats expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

New 90-day low: €5.95

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

New 90-day high: €9.20

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

New 90-day high: €8.75

Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Revenue in line with expectations

Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

Surface Oncology, Inc. Announces Preclinical Data on SRF388

New 90-day high: €6.05

New 90-day high - €5.95

Earnings released

Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Surface Oncology, Inc. Samenvatting

0.0x

-0.7x

Inkomsten en omzet